Investor Fact Sheet

Acrux is a dynamic Australian drug delivery business developing and commercialising a range of patient-preferred pharmaceutical products for global markets, using innovative, patented technology to administer drugs to humans and animals. Acrux Limited is a Pooled Development Fund. Shareholders will be entitled to concessionary tax treatment in Australia for income and capital gains derived in connection with their shareholding. Non–residents will not be subject to withholding tax on dividends paid. A shareholder or potential Shareholder should obtain their own tax advice rather than relying on this summary. Learn more about Acrux Learn more about our history

Security Information

Share Price

$0.82
0.02 (1.9%)

Open	0.80
High	0.82
Low	0.80
Volume	43,865

Acrux is listed on the Australian Securities Exchange (ASX code: ACR). View Share Price Information View Announcements & Reports

Board of Directors

Ross Dobinson — Non-Executive Chairman Bruce Parncutt — Non-Executive Director Timothy Oldham — Non-Executive Director

Michael Kotsanis — CEO & Managing Director Sharon Papworth — CFO & Company Secretary

Head Office

103-113 Stanley Street West Melbourne VIC 3003 Australia Email: investor@acrux.com.au

Share Registry

Link Market Services Level 1, 333 Collins Street MELBOURNE VIC 3000 Locked Bag A14, Sydney South, NSW 1235

Toll-free: 1300 554 474 (Australia only) International: +61 1300 554 474 Facsimile: (02) 9287 0303 Facsimile: (02) 9287 0309 (for proxy voting) Email: registrars@linkmarketservices.com.au Web: www.linkmarketservices.com.au

Auditor

Pitcher Partners Level 19, 15 William St. Melbourne VIC 3000

Telephone: +61 3 8610 5000 Facsimile: +61 3 8610 5999 info@pitcher.com.au